Disturbed cholesterol homeostasis plays critical roles in the development of multiple
diseases, such as cardiovascular diseases (CVD), neurodegenerative diseases and …

version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …

Клинические рекомендации уже давно вошли в число рабочих инструментов
современного врача, помогая ему быстро ориентироваться в наиболее эффективных …

The pharmacological treatment of dyslipidemia, a major modifiable risk factor for developing
atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial …

Background Statin intolerance limits many patients from achieving optimal low-density
lipoprotein cholesterol (LDL-C) concentrations. Current options for such patients include …

Objectives: The aim of this study was to compare biweekly and monthly evolocumab with
placebo and oral ezetimibe in patients with hypercholesterolemia in a phase III trial …

The lowering of low-density lipoprotein cholesterol (LDL-C) is the primary target of therapy in
the primary and secondary prevention of cardiovascular events. Although statin therapy is …

Despite treatment with statins, patients with elevated low-density lipoprotein cholesterol
(LDL-C) and triglycerides remain at increased risk for adverse cardiovascular events …

Statin intolerance is a clinical syndrome whereby adverse effects (AEs) associated with
statin therapy [most commonly statin‐associated muscle symptoms (SAMS)] result in the …

Drug-induced liver injury (DILI) is common and nearly all classes of medications can cause
liver disease. Most cases of DILI are benign, and improve after drug withdrawal. It is …